A Proteomic Approach to the Tumor Microenvironment An outstanding issue in treating solid cancers is understanding the complexity of this pathological tissue. Solid tumors are comprised not only of the cancer cells, but they also contain immune cells, cells that form blood vessels and lymphatic vessels, fibroblasts, and the stem cells that form the fibroblasts … Read more
How will we benefit from being able to accurately predict the peptide antigens that the immune system can recognize? Vaccine development would be a major beneficiary of such knowledge (Figure 1). We could produce more effective and safer vaccines. We could develop vaccines for pathogens for which no vaccine is currently available. We could ensure … Read more
Efforts are underway to identify the molecular reasons why some patients exhibit an enduring response to immune checkpoint inhibitor therapy. These patients have been called “exceptional” responders or “super” responders. Some patients that have cancers with a lot of DNA mutations (high mutational burden) are better responders to immune checkpoint therapy compared with patients that … Read more
The Promise of CAR T Cell Therapy Many strategies that train the immune system to recognize and attack cancer are in development or undergoing clinical trials (1). However, these strategies have the potential to cause life-threatening consequences, as evidenced by the latest report of the death of another patient receiving CAR T cell therapy (2). CAR … Read more